BrosMed Medical Announces Japanese Approval and Launch of Artimes™ and Apollo™ PTCA In Japan Market
Release time:
2017-08-30
BrosMed Medical Announces Japanese Approval and Launch of Artimes™ and Apollo™ PTCA In Japan Market Aug 30th , 2017—BrosMed Medical announces Japan PMDA approval of its Artimes™ and Apollo™ PTCA balloons, and formally launches in Japan.
BrosMed Medical Announces Japanese Approval and Launch of Artimes™ and Apollo™ PTCA In Japan Market
Aug 30th , 2017—BrosMed Medical announces Japan PMDA approval of its Artimes™ and Apollo™ PTCA balloons, and formally launches in Japan. Artimes™ and Apollo™ are two PTCA of Brosmed balloon families. Artimes™ is a semi-compliant pre-dilatation PTCA balloon, and Apollo™ is a non-complaint high pressure post-dilatation PTCA balloon. These two balloons are designed for the treatment of percutaneous transluminal coronary angioplasty (PTCA) for the purpose of improving myocardial blood flow in the localized stenotic lesion of the coronary arteries.
Following the approval, BrosMed Medical achieves one more step to its global vision beside current geographical footprint in Europe, USA, China, Asia Pacific, Latin America and Middle East.
“The PMDA approval of Artimes™ and Apollo™ PTCA in Japan is quite exciting and significant to the company.” said by Stephen Lee, General Manager of BrosMed Medical. “PMDA approval helps BrosMed to penetrate the Japan market and compete ourselves with giant companies and local players in term of products performance and services. We are confident that Artimes™ and Apollo™ would satisfy Japanese physicians’ needs and provide better clinical outcomes. Moreover, we are going to provide our completed PTA portfolio to the Japan market as second step in order to expand us from cardiovascular to endovascular filed.”
Please contact our regional distributors and/or our sales at sales@brosmed.com for more products details.
About BrosMed Medical
BrosMed Medical is more than just a company; we are leading the medical device design and manufacturing revolution.
BrosMed Medical develops, manufactures and markets medical devices primarily used by interventional cardiologists, radiologists and vascular surgeons in angioplasty procedures and other minimal invasive devices.
We provide solutions to our customers through innovative design, effective supply chain management, world-class manufacturing, and flexible channels of distribution and through the development or acquisition of innovative technologies.
BrosMed Medical product portfolio consist of, Artimes™ PTCA, Apollo™NC PTCA, Atropos™ 0.035 PTA, Minerva™ 0.018 PTA, Polux™ 0.014 PTA, Hermes™ NC 0.035 PTA, Achilles™ NC 0.018 PTA, Castor™ NC 0.014 PTA, Conger™ Hydrophilic coated wireandFreepath™ Catheter Sheath Introducer. BrosMed Medical is supplying safe, effective and hi-tech medical devices in 30 countries.
Join with Us!
Please fill out this form and we will get in touch within 24 hours.
* Note: Please be sure to fill in the information accurately and keep the communication unblocked. We will get in touch with you as soon as possible.
More news
BrosMed Announced CE MDR Approval of New Generation Conger™ Plus Hydrophilic Guidewires
Designed for superior crossability and maneuverability in peripheral interventions, Conger Plus now offers 116 models with expanded sizes (OD 0.018'' to 0.038'') and lengths (up to 300cm).
2025-04-25
Meet BrosMed at ESC Congress 2024
BrosMed Medical is delighted to participate in the ESC Congress 2024 from August 30th to September 2nd in London, UK.
2024-08-15
BrosMed Medical Announces Scott J. Addonizio as Chief Operating Officer
2024 August 1st – BrosMed Medical is pleased to announce the appointment of Scott J. Addonizio as its Chief Operating Officer (COO), effective immediately. Mr. Scott J. Addonizio brings a wealth of experience and expertise to BrosMed, with a distinguished career spanning almost 30 years in the medical device industry. Prior to joining BrosMed, Mr. Addonizio served as SVP at Cordis and COO at MedAlliance Swiss Medical Technology.
2024-08-01
CTO&CHIP PCI – Insights from the clinical practice (Ⅱ)
July 30, 2024 @16:00-17:30 (Beijing Time) Join BrosMed Medical on Tuesday, July 30 for an enlightening discussion that unites cardiologists from Malaysia, China, India, Tunisia and Portugal, where clinical expertise harmoniously fuses with CTO&CHIP innovation. At this exclusive webinar, we’re orchestrating a confluence of valuable insights, drawing from the collective wisdom of seasoned interventional cardiologists.
2024-07-26
BrosMed Announced CE MDR Approval of New Generation PTA SC Balloon Dilatation Catheters
May 27, 2024- BrosMed announced that it receives European Medical Device Regulation (MDR) certification for the New Generation PTA SC Balloon Dilatation Catheters (Brand Name: Polux™ Pro 014, Minerva™ Pro 018 and Atropos™ Pro 035).
2024-05-27